Douglas Treco is Chief Executive Officer and Chairman of Inozyme Pharma, Inc. (INZY). The company reported total compensation of $2,485,392 for fiscal year 2024.
| Salary | $541,667 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,933,375 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $10,350 |
| Total | $2,485,392 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Inozyme Pharma, Inc. filed April 29, 2025, accession 0000950170-25-060198.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | Chief Executive Officer and Chairman | $541,667 | $0 | $0 | $1,933,375 | $0 | $0 | $10,350 | $2,485,392 |
| FY2023 | Chief Executive Officer and Chairman | $375,000 | $7,500 | $573,000 | $4,134,601 | $200,000 | $0 | $9,375 | $5,299,476 |
Totals as disclosed in each year's own compensation disclosure for Inozyme Pharma, Inc..
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Douglas Treco this page | Chief Executive Officer and Chairman | $2,485,392 |
| Matthew Winton | Senior Vice President and Chief Operating Officer | $1,764,899 |
| Sanjay Subramanian | Senior Vice President and Chief Financial Officer and Head of Business Development | $1,703,737 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Inozyme Pharma, Inc. compensation brief.
Douglas Treco's compensation sits inside Inozyme Pharma, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.